Jonathan Benzaquen

Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

Charles‐Hugo Marquette, Jacques Boutros, Jonathan Benzaquen et al. · The Lancet Respiratory Medicine · 2020 · 136 citations · Full text

Medicine, Oncology, Cancer Screening +16

A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy

Laëtitia Douguet, Séréna Janho dit Hreich, Jonathan Benzaquen et al. · Nature Communications · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

David Chardin, M. Paquet, Renaud Schiappa et al. · Journal for ImmunoTherapy of Cancer · 2020 · 84 citations · Full text

Medicine, Oncology, Pharmacology +16

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients

Véronique Hofman, Isabelle Rouquette, Élodie Long-Mira et al. · Journal of Thoracic Oncology · 2019 · 49 citations · Full text

Medicine, Molecular Biology, Oncology +12

Allergy Evaluation of Hypersensitivity to Platinum Salts and Taxanes: A Six-Year Experience

J. Pradelli, Paul Verdoire, Jacques Boutros et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 41 citations

Life Sciences, Immunology, Allergy +11